Inhibiting the Energy Factory of Oral Cancer Cells: ALDOA and PGK1 Dual Blockade Demonstrates Anti-Cancer Synergy
Background
Oral Squamous Cell Carcinoma (OSCC) is the most common and highly fatal type of oral malignancy. Early diagnosis is challenging, and rapid invasion into surrounding tissues results in poor patient prognosis. Furthermore, cancer cells often acquire resistance to existing targeted therapies, making the development of new treatments an urgent task.
Recent studies have highlighted metabolic reprogramming as a key driver of cancer growth and metastasis. Unlike normal cells, cancer cells rely on a unique metabolic pathway in which they rapidly obtain energy by breaking down glucose into lactate even in oxygen-rich environments. Attempts have been made to control cancer cells by blocking this metabolic pathway; however, limitations have been encountered due to the use of alternative pathways or the blockage of only specific enzymes, which do not completely halt cancer progression. There is a need for a systematic approach to identify and target key metabolic proteins that can effectively control tumor growth by elucidating the metabolic characteristics of OSCC patients.
Key Findings
The researchers linked patient-derived data with gene screening technology to investigate the metabolic vulnerabilities of OSCC cells. They first analyzed transcriptomic data from the TCGA-OSCC cohort to identify a combination of prognostic genes. Subsequently, they linked this data with large-scale CRISPR-Cas9 dependency data from the Cancer Dependency Map (DepMap) to successfully narrow down the key metabolic targets essential for tumor survival.
Through this process, Aldolase A (ALDOA) and Phosphoglycerate Kinase 1 (PGK1), glycolytic enzymes, were identified as promising target proteins for OSCC. Analysis of survival data from OSCC patients revealed that patients with high expression levels of ALDOA and PGK1 had shorter overall survival compared to a control group with low expression levels. This provides empirical evidence that these two proteins significantly contribute to cancer cell survival and poor prognosis.
Inhibition of ALDOA or PGK1 expression using gene silencing technology resulted in a decrease in glycolytic activity in cancer cells. This was clearly demonstrated by a reduction in the extracellular acidification rate (ECAR), an indicator of lactate secretion by cancer cells. Metabolic blockade not only inhibited the proliferation of cancer cells in vitro but also slowed tumor growth in animal models.
Furthermore, the researchers investigated the synergistic effect of simultaneously inhibiting both glycolytic enzymes. Bliss independence analysis revealed a significant synergistic effect when the ALDOA inhibitor Aldometanib and the PGK1 inhibitor CBR-470-1 were used in combination. In animal experiments using a mouse xenograft model, the combination therapy group showed significantly higher tumor suppression rates compared to the monotherapy groups.
Significance and Prospects
This study demonstrates that targeting multiple points in the glycolytic pathway can effectively block the metabolic bypass routes of cancer cells. This dual blockade strategy overcomes the limitations of existing single-target metabolic therapies, which have faced challenges with drug resistance and incomplete efficacy. This research is expected to expand the clinical applicability of metabolic therapies and broaden the existing treatment paradigm.
However, there are still some obstacles to overcome before clinical application. ALDOA and PGK1 are involved in glucose metabolism not only in cancer cells but also in normal cells, so a strategy to address systemic toxicity needs to be established. Furthermore, it remains to be confirmed whether the therapeutic efficacy observed in animal models can be safely reproduced in humans, which is another challenge to be addressed in the future.
BACKGROUND: Oral squamous cell carcinoma (OSCC) is associated with high mortality and limited effective targeted therapies. Although metabolic reprogramming is closely linked to malignancy, the key metabolic regulators that functionally drive OSCC progression and may serve as therapeutic targets remain incompletely defined. METHODS: We combined clinical transcriptomic analysis with functional genomic screening to identify metabolic vulnerabilities in OSCC. A Least Absolute Shrinkage and Selection Operator (LASSO)-derived prognostic gene signature was constructed using transcriptomic data from The Cancer Genome Atlas (TCGA)-OSCC cohort. To prioritize functionally critical targets, gene essentiality and tumor selectivity were evaluated using large-scale CRISPR-Cas9 dependency data from the Cancer Dependency Map (DepMap) project. RESULTS: This analysis identified Aldolase A (ALDOA) and Phosphoglycerate Kinase 1 (PGK1) as candidate targets with prognostic relevance and strong dependency across OSCC cell lines. Elevated expression of ALDOA and PGK1 was significantly associated with poor patient survival. Mechanistically, genetic silencing of ALDOA or PGK1 impaired glycolytic activity, as evidenced by reduced extracellular acidification rates (ECAR), and suppressed tumor cell proliferation in vitro and in vivo. Furthermore, combined targeting of these two glycolytic enzymes produced synergistic anti-tumor effects. Bliss independence analysis showed synergy between the ALDOA inhibitor Aldometanib and the PGK1 inhibitor CBR-470-1, and the combination produced greater tumor suppression than either monotherapy in xenograft models. CONCLUSION: Our findings indicate that ALDOA and PGK1 contribute to metabolic reprogramming and poor prognosis in OSCC. These findings support further evaluation of dual ALDOA and PGK1 inhibition as a potential therapeutic strategy for OSCC.
This study provides a practical scenario that could serve as a new milestone in oral cancer treatment. The most anticipated application is the introduction of a companion diagnostic system that analyzes the expression levels of ALDOA and PGK1 during the diagnosis of oral cancer patients. For example, at the tissue biopsy stage, patients with high activity of both enzymes can be identified, and the possibility of poor prognosis can be predicted in advance. This allows for a personalized metabolic therapy scenario in which the combination therapy of Aldometanib and CBR-470-1 is prioritized for this patient group. In addition, it may provide a new route of attack by blocking the glycolytic pathway for patients with recurrent oral cancer who have developed resistance to existing chemotherapy. By securing a combination therapy option for these patients with difficult-to-treat cancers, it will contribute to improving treatment outcomes in clinical practice.